Cyclosporin A
Catalog #:
IN0041Shipping advice:
Suitable for Express Delivery only (1-day). International shipping rate please contact us for details
| IN0041-100mg | USD66.0 |
| IN0041-500mg | USD256.0 |
Synonyms: Cyclosporin A, Ciclosporin, Cyclosporine, Cyclosporin
IUPAC Name:
(E)-14,17,26,32-tetrabutyl-5-ethyl-8-(1-hydroxy-2-methylhex-4-enyl) -1,3,9,12,15,18,20,23,27-nonamethyl-11,29-dipropyl-1,3,6,9,12,15,18,21,24,27,30- undecaazacyclodotriacontan-2,4,7,10,13,16,19,22,25,28,31-undecaoneFunctional Activity:
Cyclosporin A is an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the immune system, and therefore the risk of organ rejection. Initially isolated from the fungus Tolypocladium inflatum isolated from a soil sample obtained by Sandoz scientists at Hardangervidda, Norway in 1969, it is a cyclic nonribosomal peptide of 11 amino acids and contains a single D-amino acid, which are rarely encountered in nature.
Cyclosporin A (cyclosporine, cyclosporin ) is thought to bind to the cytosolic protein cyclophilin (immunophilin) of immunocompetent lymphocytes, especially T-lymphocytes. This complex of ciclosporin and cyclophilin inhibits calcineurin, which, under normal circumstances, is responsible for activating the transcription of interleukin 2. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor NF-AT (nuclear factor of activated T-cells), which moves to the nucleus of the T-cell and increases the activity of genes coding for IL-2 and related cytokines. Cyclosporin A (cyclosporine, cyclosporin) prevents the dephosphorlyation of NF-AT by binding to cyclophilin.
Technical Data:
M.Wt: 1202.63
Formula: C62H111 N11O12
Solubility: Soluble to 100 mM in DMSO and to 50 mM in ethanol
Purity: >98%
Storage: Dessicate at -20 degree C
CAS No.: 59865-13-3
Related Products by Target:
Solubility: Soluble to 100 mM in DMSO and to 50 mM in ethanol
Purity: >98%
Storage: Dessicate at -20 degree C
CAS No.: 59865-13-3
Related Products by Target:
Storage: Dessicate at -20 degree C
CAS No.: 59865-13-3
Related Products by Target:
Related Products by Target:
References for Cyclosporin A:
1. Ohtsuka, T. Successful oral cyclosporin therapy for Henoch-Schonlein purpura nephropathy. J Dermatol, 36: 314-316, 2009.
2. Gupta, V. and Bhatia, B. Antithymocyte globulin and cyclosporin in children with acquired aplastic anemia. Indian J Pediatr, 76: 970-971; author reply 971-972, 2009.
3. Sanchez Perez, B., Aranda Narvaez, J. M., Suarez Munoz, M. A., Fernandez Aguilar, J. L., Gonzalez Sanchez, A. J., Perez Daga, J. A., and Santoyo Santoyo, J. Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels. Transplant Proc, 41: 1028-1029, 2009.
4. Abe, M., Syuto, T., Hasegawa, M., Yokoyama, Y., and Ishikawa, O. Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxacalcitol ointment for patients with moderate psoriasis vulgaris. J Dermatol, 36: 197-201, 2009.
5. Wilhelm, A. J., den Burger, J. C., Vos, R. M., Chahbouni, A., and Sinjewel, A. Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 877: 1595-1598, 2009.
6. Franchi, C., Frigerio, E., Spadino, S., Garutti, C., Colombo, D. M., Altomare, A., and Altomare, G. Hepatitis C viral load decreases after cyclosporin treatment for erosive lichen planus. Clin Exp Dermatol, 34: e254-255, 2009.
7. Li, S. Q., Zhang, Y., and Tang, D. B. Possible mechanisms of Cyclosporin A ameliorated the ischemic microenvironment and inhibited mitochondria stress in tree shrews' hippocampus. Pathophysiology, 16: 279-284, 2009.
8. Pagel, P. S. and Krolikowski, J. G. Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporin A in rabbits. Anesth Analg, 108: 1076-1082, 2009.
9. Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K., Baynes, A. C., O'Neill, N., Fildes, J. E., Yonan, N., and Williams, S. G. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation, 87: 771-775, 2009.
10. Shitara, Y., Nagamatsu, Y., Wada, S., Sugiyama, Y., and Horie, T. Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab Dispos, 37: 1172-1178, 2009.
